Physician profile
Steven Borzak
NPI 1427031848
$5,567.79
in general payments reported to CMS, 2019-2025
28 companies · $756 in 2025
The $756 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,619 · 2020: $1,043 · 2021: $1,058 · 2022: $183 · 2023: $538 · 2024: $370 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.68 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $820.89 | 2019-2024 | |
| Amgen INC. | $611.15 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $549.26 | 2019-2025 | Lokelma, Farxiga |
| Abbott Laboratories | $493.14 | 2019-2024 | Aveir, Amplatzer Amulet |
| Boston Scientific Corporation | $300.14 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Sanofi-Aventis U.S. LLC | $299.79 | 2019-2021 | |
| Abiomed | $294.82 | 2024-2025 | Impella |
| Amarin Pharma, INC. | $229.86 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $201.67 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $199.78 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.40 | 2019-2021 | |
| Esperion Therapeutics, INC. | $193.46 | 2020-2021 | |
| Pfizer INC. | $167.85 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $159.83 | 2021-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $140.00 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $125.00 | 2019 | |
| Edwards Lifesciences Corporation | $113.82 | 2019 | |
| Medtronic Vascular, INC. | $93.58 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $76.38 | 2019 | |
| Alnylam Pharmaceuticals INC. | $69.38 | 2024-2025 | Onpattro |
| Heartflow, INC. | $58.22 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $53.96 | 2024-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.53 | 2020 | |
| Cvrx, INC. | $21.13 | 2025 | Barostim Neo System |
| Akcea Therapeutics, INC. | $21.10 | 2020 | |
| Snap Diagnostics LLC | $17.64 | 2019 | |
| Gilead Sciences, INC. | $17.06 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Borzak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.